CRO Fortrea 'dis­putes the ac­cu­ra­cy' of Ace­lyrin's claims about im­munol­o­gy drug tri­al con­duct

Af­ter Ace­lyrin said that a con­tract re­search or­ga­ni­za­tion and its ven­dor made “clin­i­cal tri­al ex­e­cu­tion er­rors” in a study of the biotech’s lead im­munol­o­gy treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.